Abstract: A container adapter plate having two layers that is adapted for use with an attachment apparatus and/or system for securely attaching objects to a bicycle frame.

Abstract: An attachment apparatus and/or system for securely attaching objects to a bicycle frame having a transport platform that is attachable to the top of a bicycle rack.

Abstract: An attachment apparatus and/or system for securely attaching objects to a bicycle frame having a transport platform that is attachable to the top of a bicycle rack.

Abstract: The present disclosure is directed to an attachment apparatus and/or system for securely attaching objects to a bicycle frame that comprises a transport platform that is attachable to the top of a bicycle rack.

Abstract: The present disclosure is directed to an attachment apparatus and/or system for securely attaching objects to a bicycle frame that comprises a transport platform that is attachable to the top of a bicycle rack.

Abstract: The present invention relates to a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan. It also relates to the use of a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, as active ingredient for preventing and/or treating the retinal neurodegeneration induced by diabetes and/or aging.

Abstract: The present invention relates to a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan. It also relates to the use of a topical ophthalmic formulation comprising at least one antagonist of the endothelin receptor, preferably selected from sitaxentan, ambrisentan, atrasentran, bosentan, macitentan and tezosentan, or a mixture thereof, more preferably bosentan, as active ingredient for preventing and/or treating the retinal neurodegeneration induced by diabetes and/or aging.

Abstract: The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.

Abstract: A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2?) at 11.2°, 19.9°, 20.7° and 34.1°±0.2° is administered to a patient in need thereof.

Abstract: A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2?) at 11.2°, 19.9°, 20.7° and 34.1°±0.2° is administered to a patient in need thereof.

Abstract: The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Abstract: The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.

Abstract: The present invention relates to a bilayer tablet which comprises a compartment containing a pharmaceutically acceptable simvastatin compound as its active ingredient; and at the same time a separate compartment containing a pharmaceutically acceptable lisinopril compound and a pharmaceutically acceptable folic acid compound as active ingredients, for the prevention of stroke in high-risk conditions or diseases.

Abstract: The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Abstract: The present invention relates to hypocholesterolemic compositions comprising statins plus antiflatulent agents. In particular the compositions of the present invention comprise a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, whether in free form or as pharmaceutically acceptable salts and hydrates thereof, plus an antiflatulent agent. selected from the group consisting of simethicone and dimethicone. The combination of statins plus antiflatulent agents is useful in the prevention and management of flatulence caused by statins.

Abstract: Prolonged-release diuretic compositions containing torasemide as active ingredient The compositions of the invention are useful to be able to avoid the troublesome unitary urgencies caused by conventional immediate-release compositions.

Abstract: Pharmaceutical compositions useful for treating dermal diseases caused by fungi and yeasts with inflammation and/or associated with a bacterial infection. Such compositions contain a therapeutically effective amount of sertaconazole, or a pharmaceutically acceptable salt, solvate, isomer thereof or mixtures thereof; and a therapeutically effective amount of at least one compound selected from the group consisting of hydrocortisone, a pharmaceutically acceptable ester of hydrocortisone, an antibacterial quinolone compound, and mixtures thereof.

Abstract: The invention relates to monodose mucoadhesive vaginal compositions of sertaconazole or a pharmaceutically acceptable salt thereof for the treatment of vulvovaginal candidiasis.